Evaluation of antifungals in the surgical intensive care unit: A multi-institutional study

Mycoses

Volumn 49, Issue 3, 2006, Pages 226-231

  Garey, Kevin W ^a   Neuhauser, Melinda M ^a   Bearden, David T ^b   Cannon, Joan P ^c   Lewis, Russell E ^a   Gentry, Layne O ^d   Kontoyiannis, Dimitrios P ^e  

^a UNIVERSITY OF HOUSTON   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c HINES VA HOSPITAL   (United States)

^d ST LUKE S EPISCOPAL HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Antifungal; Fluconazole; Intensive care unit; Pharmacoepidemiology

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL THERAPY; CANDIDA; CANDIDIASIS; CRITICALLY ILL PATIENT; DEMOGRAPHY; DRUG INDICATION; DRUG USE; EMPIRICAL THERAPY; EMPIRICISM; FEMALE; FUNGAL COLONIZATION; FUNGEMIA; FUNGUS CULTURE; HOSPITAL; HUMAN; INTENSIVE CARE; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MULTICENTER STUDY; MYCOSIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SURGICAL INTENSIVE CARE; TREATMENT DURATION; UNITED STATES; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDIASIS; CROSS INFECTION; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SURGERY;

CANDIDA; FUNGI; SICUS;

EID: 33646228401     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2006.01222.x     Document Type: Review

References (19)

1. Bonten MJ Weinstein RA. Bird's-eye view of nosocomial infections in medical ICU: blue bugs, fungi, and device-days Crit Care Med 1999 27 853 4
2. Vincent JL Anaissie E Bruining H et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care Intensive Care Med 1998 24 206 16
3. Berrouane YF Herwaldt LA Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital J Clin Microbiol 1999 37 531 7
4. Leather HL Wingard JR. Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom? Curr Opin Infect Dis 2002 15 369 75
5. American Hospital Association Hospital Statistics 2001 Edition Chicago, IL Chicago Health Forum LLC, an affiliate of the American Hospital Association 2000
6. Charlson ME Pompei P Ales KL MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 1987 40 373 83
7. Meis JF Verweij PE. Current management of fungal infections Drugs 2001 61 Suppl. 1 13 25
8. Piarroux R Grenouillet F Balvay P et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients Crit Care Med 2004 32 2443 9
9. Pappas PG Rex JH Sobel JD et al. Guidelines for treatment of candidiasis Clin Infect Dis 2004 38 161 89
10. Eggimann P Garbino J Pittet D. Management of Candida species infections in critically ill patients Lancet Infect Dis 2003 3 772 85
11. Ascioglu S Rex JH de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus Clin Infect Dis 2002 34 7 14
12. Marchetti O Bille J Fluckiger U et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000 Clin Infect Dis 2004 38 311 20
13. Price MF LaRocco MT Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period Antimicrob Agents Chemother 1994 38 1422 4
14. Antoniadou A Torres HA Lewis RE et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy Medicine (Baltimore) 2003 82 309 21
15. Hope W Morton A Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use J Hosp Infect 2002 50 56 65
16. Nguyen MH Peacock JE Jr. Morris AJ et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance Am J Med 1996 100 617 23
17. Natsch S Steeghs MH Hekster YA Meis JF van der Meer JW Kullberg BJ. Use of fluconazole in daily practice: still room for improvement J Antimicrob Chemother 2001 48 303 10
18. Kontoyiannis DP Reddy BT Torres HA et al. Pulmonary candidiasis in patients with cancer: an autopsy study Clin Infect Dis 2002 34 400 3
19. Keating G Figgitt D. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis Drugs 2003 63 2235 63